
Alphinity Concentrated Australian Share Fund
Fund Overview
A well-diversified, high conviction concentrated portfolio of listed Australian stocks. Suitable for investors aiming for a higher return and prepared to take additional volatility.
Consistent relative returns
Aims to deliver consistent incremental outperformance at comfortable levels of volatility.
Style agnostic
Invest in a wide variety of stocks through different market cycles as we aim to own companies at the right time in their earnings cycle.
Concentrated
An actively managed long only portfolio of 20-35 high conviction quality large-cap Australian listed stock.
Robust process
A disciplined and repeatable process that have been used by the investment team of co-portfolio managers since 2004, combining fundamental and quantitative research that results in a strong buy and sell discipline.
Fund Performance & Characteristics
Fund | Alphinity Concentrated Australian Share Fund |
Investment objective | To outperform the benchmark after costs over rolling five year periods |
Benchmark | S&P/ASX 200 Accumulation Index |
Stocks held in portfolio | 20-35 stocks |
Minimum investment timeframe | At least five years |
Minimum initial investment | $10,000 or $1,000 with Regular Savings Plan |
Management fee | 0.80% p.a. |
Performance fee | 15% of the Fund’s return above the S&P/ASX 200 Accumulation Index |
Distribution frequency | Quarterly |
APIR code | HOW0026AU |
mFund ticker | ALH02 |
Performance (after fees) as at 31 July 2025
Alphinity Concentrated Australian Share Fund | Quarter (%) | 1 year (%) | 3 years (% p.a.) | 5 years (% p.a.) | 7 years (% p.a.) | 10 years (% p.a.) | Since inception (% p.a.) | ||
---|---|---|---|---|---|---|---|---|---|
Alphinity Concentrated Australian Share Fund | 31 July 2025 | 8.5 | 15.1 | 12.9 | 12.2 | 8.8 | 9.6 | 10.4 | 3 |
S&P/ASX 200 Accumulation Index | 31 July 2025 | 8.2 | 11.8 | 12.3 | 12.3 | 8.9 | 8.6 | 9.1 | 5 |
Alphinity Concentrated Australian Share Fund: the Fund changed investment manager and investment methodology on 12 July 2010, at which time Alphinity Investment Management commenced managing the Funds and started transitioning of the portfolios to a structure consistent with Alphinity’s investment philosophy. The transition was completed on 31 August 2010. Therefore, the inception date for the returns for the Fund is 1 September 2010.
For performance for previous periods please contact Fidante. Returns are calculated after fees have been deducted assuming reinvestment of distributions. No allowance is made for tax. Past performance is not a reliable indicator of future performance.

How to invest
To find out more about the Alphinity Concentrated Australian Share Fund, contact your local Fidante Business Development Manager.
For step by step instructions on how to invest, visit the Invest Online page of our website.
Before making a decision about whether to make an investment or additional investment in one of our funds please read the Fund’s Target Market Determination (TMD), Product Disclosure Statement (PDS), Additional Information Booklet and Product Updates to ensure the key attributed of the fund as described in the TMD and PDS aligns with your objectives, financial situation and needs.
Fund Documents
Australian Funds Investment Team
Latest Insights

On the Road with Alphinity: ESG and sustainability priorities in Western Australia’s mining sector
In this report, research in Western Australia with mining companies and Traditional Owner groups explored cultural heritage obligations and environmental impacts. The findings inform an assessment of key ESG risks, including nature, decarbonisation, First Nations considerations, AI, and workforce safety.

Two hot stocks from the market’s hottest sector this year (and no, it’s not tech!)
Telstra’s dominance, Spark’s revival, and sector-wide discipline are fuelling the ASX telco rally. Here’s what could happen next.

Australian Webcast: Aus vs US Healthcare Sectors & why we still like Resmed
Elfreda Jonker speaks with Stuart Walsh about why Australia’s healthcare sector has outperformed global peers, thanks to niche leaders like CSL, ResMed, and Cochlear that are less affected by US policy headwinds. ResMed in particular has benefited from strong demand, product innovation, and competitor exits, driving an ongoing earnings upgrade cycle and healthy shareholder returns.

Stock picking, banks & a home bias
PODCAST: From banks to resources, Australian investors continue to have a home bias. But with uncertainty around positioning on the ASX, should investors remain heavy weight local market?
Ready to invest in the Alphinity Concentrated Australian Share Fund?